Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
New England Journal of Medicine2021Vol. 384(11), pp. 1003–1014
Citations Over TimeTop 1% of 2021 papers
Lawrence Corey, Peter B. Gilbert, Michal Juraska, David C. Montefiori, Lynn Morris, Shelly Karuna, Srilatha Edupuganti, Nyaradzo Mgodi, Allan C. deCamp, Erika Rudnicki, Yunda Huang, Pedro Gonzáles, Robinson Cabello, Catherine Orrell, Javier R. Lama, Fatima Laher, Erica Lazarus, Jorge Sánchez, Ian Frank, Juan Hinojosa, Magdalena E. Sobieszczyk, Kyle Marshall, Pamela Mukwekwerere, Joseph Makhema, Lindsey R. Baden, James I. Mullins, Carolyn Williamson, John Hural, M. Juliana McElrath, Carter Bentley, Simbarashe Takuva, Margarita M. Gomez Lorenzo, David Burns, Nicole Espy, April K. Randhawa, Nidhi Kochar, Estelle Piwowar‐Manning, Deborah Donnell, Nirupama Sista, P. Andrew, James G. Kublin, Glenda Gray, Julie E. Ledgerwood, John R. Mascola, Myron S. Cohen
Abstract
VRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates provided proof-of-concept that bnAb prophylaxis can be effective. (Supported by the National Institute of Allergy and Infectious Diseases; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 ClinicalTrials.gov numbers, NCT02716675 and NCT02568215.).
Related Papers
- → Production of a chimeric flavivirus that contains the major structural glycoprotein genes of T’Ho virus in the genetic background of Zika virus(2023)1 cited
- → Analysis of a Primary Isolate-like Virus from Simian and Human Immunodeficiency Virus-Infected Macaque Having Broad Neutralizing Activity(2002)2 cited
- → Competitive virus assay method for titration of noncytopathogenic bovine viral diarrhea viruses (END+ and END− viruses)(2012)2 cited
- → The Virulence of West Nile Virus and TP 21 Virus and Their Application to a Group B Arbor Virus Vaccine(1961)15 cited
- → Murine Xenotropic Type C Viruses. IV. Replication and Pathogenesis in Ducks(1982)6 cited